R&D the core of Flavii
Flavii Therapeutics aims to develop innovative epigenetic therapies for central nervous system disorders. To date, we have identified five promising epigenetic drugs in various stages of preclinical development, with Oxapi-27 being the most advanced, now on the verge of entering regulatory preclinical studies.
THERAPEUTIC FOCUS
ABOUT ALZHEIMER
Alzheimer’s disease (AD) is a progressive neurodegenerative condition that causes memory loss, confusion, and severe cognitive decline. It is the most common form of dementia, affecting approximately 5–7% of people aged 65 and older.
OUR SCIENTIFIC APPROACH
Epigenetic mechanisms, which regulate gene expression without altering the underlying DNA sequence, are increasingly recognized for their potential to modulate disease pathways in ways that conventional therapies cannot.
PIPELINE
At Flavii, our focus is the development of innovative epigenetic therapies designed to improve outcomes for patients with CNS conditions.
RELIED UPON BY TOP RESEARCH INSTITUTIONS ACROSS THE GLOBE.
Select scientific publications from Flavii employees, founders and collaborators:
At Flavii, we are committed to making epigenetic treatments available for patients suffering from CNS disorders. We strongly believe we can succeed in meaningfully improving the lives of patients and their families.